Hasan Kawa M
Department of Medicine, College of Medicine, Hawler Medical University, Erbil, Iraq.
Department of Clinical Haematology, Nanakaly Hospital for Blood Diseases & Oncology, Erbil, Iraq.
Sultan Qaboos Univ Med J. 2018 Nov;18(4):e461-e467. doi: 10.18295/squmj.2018.18.04.006. Epub 2019 Mar 28.
Chronic lymphocytic leukaemia (CLL) is characterised by an accumulation of clonal B cells in the blood, bone marrow and lymphatic tissue. This study aimed to evaluate the clinical and immunophenotypic characteristics and survival rate of CLL patients.
This retrospective study was conducted at the Nanakaly Hospital for Blood Diseases & Oncology in Erbil, Iraq, between January 2011 and December 2017. A total of 105 CLL patients were assessed to determine clinical presentation and staging, immunophenotype and survival rate.
The median age of the patients was 65 years and 63.8% were male. The main clinical presentations were splenomegaly (64.8%), pallor (61.9%) and lymphadenopathy (60%). More than half of the patients presented at an advanced clinical stage according to the Rai and Binet staging systems (59.1% and 55.2%, respectively). All CLL cases expressed both cluster of differentiation (CD)19 and CD5, 67.6% had monoclonal kappa light chains and 21% expressed CD38. The five-year overall survival (OS) rate was 61.3%. The mean duration of five-year survival was 41.3 months (95% confidence interval: 36.4-46.3 months). There were no correlations between survival and sociodemographic, clinical or laboratory characteristics.
In comparison to the existing Western literature, Iraqi CLL patients more frequently presented with hepatosplenomegaly and at a more advanced clinical stage. In addition, the five-year OS rate was much lower.
慢性淋巴细胞白血病(CLL)的特征是克隆性B细胞在血液、骨髓和淋巴组织中积聚。本研究旨在评估CLL患者的临床和免疫表型特征及生存率。
本回顾性研究于2011年1月至2017年12月在伊拉克埃尔比勒的纳纳卡利血液病与肿瘤医院进行。共评估了105例CLL患者,以确定临床表现和分期、免疫表型及生存率。
患者的中位年龄为65岁,男性占63.8%。主要临床表现为脾肿大(64.8%)、面色苍白(61.9%)和淋巴结病(60%)。根据Rai和Binet分期系统,超过一半的患者处于临床晚期(分别为59.1%和55.2%)。所有CLL病例均表达分化簇(CD)19和CD5,67.6%有单克隆κ轻链,21%表达CD38。五年总生存率(OS)为61.
3%。五年生存的平均持续时间为41.3个月(95%置信区间:36.4 - 46.3个月)。生存与社会人口统计学、临床或实验室特征之间无相关性。
与现有的西方文献相比,伊拉克CLL患者肝脾肿大更为常见,临床分期更晚。此外,五年OS率要低得多。